PLEKHF1 Induces Mitochondrial Dysfunction to Inhibit Osteosarcoma Growth and Metastasis
IUBMB Life · 2025
DOI: 10.1002/iub.70048 ↗Kurz gefasst
Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Jun Wan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Osteosarcoma, Mitochondria, Bone Neoplasms, Lung Neoplasms. Die Arbeit nennt 58 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan, China.
Abstract (Originalsprache)
Osteosarcoma (OS) is an uncommon malignancy with stagnant survival rates over the past four decades and early‐stage metastasis, predominantly affecting children and adolescents. This study identified significant metabolic differences between metastatic and non‐metastatic OS samples through bioinformatics analysis, highlighting key processes such as cell proliferation, mitochondrial assembly, and changes in mitochondrial membrane permeability. Among differentially expressed genes, Pleckstrin Homology And FYVE Domain Containing 1 (PLEKHF1) was the most significantly downregulated in metastatic OS samples. Functional experiments demonstrated that PLEKHF1 overexpression in Saos‐2 and U2OS cells induced mitochondrial dysfunction, evidenced by increased mtROS levels, decreased mitochondrial membrane potential, and altered cytochrome C distribution. Additionally, PLEKHF1 overexpression inhibited OS cell viability, colony formation, migration, invasion, and epithelial‐mesenchymal transition (EMT), while promoting apoptosis. Conversely, knockdown of PLEKHF1 had the opposite effects on Saos‐2 and U2OS cells. In vivo, PLEKHF1 overexpression reduced tumor growth and lung metastasis in a mouse model. Conversely, PLEKHF1 knockdown ameliorated Rotenone‐induced mitochondrial dysfunction and mitophagy, partially reversing the suppressive effects of Rotenone on OS cell aggressiveness. These findings suggest that PLEKHF1 could serve as an anti‐tumor factor by inducing mitochondrial dysfunction, thereby inhibiting OS growth and metastasis. The study highlights the potential of PLEKHF1 as a therapeutic target for managing osteosarcoma, providing valuable insights into the role of mitochondrial dysfunction in OS pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
ORCID-Profile: Feng Long
Förderung
- Natural Science Foundation of Hunan, China
Zitieren
APA
Wan, J., Cai, X., Liao, Z., Liu, Y., Liu, Q., Zhang, C., & Long, F. (2025). PLEKHF1 Induces Mitochondrial Dysfunction to Inhibit Osteosarcoma Growth and Metastasis. IUBMB Life. https://doi.org/10.1002/iub.70048
Vancouver
Wan J, Cai X, Liao Z, Liu Y, Liu Q, Zhang C, et al. PLEKHF1 Induces Mitochondrial Dysfunction to Inhibit Osteosarcoma Growth and Metastasis. IUBMB Life. 2025. doi:10.1002/iub.70048
BibTeX
@article{Wan2025,
author = {Wan, Jun and Cai, Xinyan and Liao, Zhan and Liu, Yupeng and Liu, Qing and Zhang, Can and Long, Feng},
title = {PLEKHF1 Induces Mitochondrial Dysfunction to Inhibit Osteosarcoma Growth and Metastasis},
journal = {IUBMB Life},
year = {2025},
doi = {10.1002/iub.70048}
}
EUVIMED